Fortress Biotech, Inc.
جودة البيانات: 100%
KWD 2.35
▼
KWD 0.05
(-2.08%)
القيمة السوقية: 76.80 M
السعر
KWD 2.39
القيمة السوقية
76.80 M
نطاق اليوم
—
نطاق 52 أسبوعًا
—
حجم التداول
—
فتح —
متوسط 50 يوم / 200 يوم
—
متوسط 50 يوم / 200 يوم
—
Quick Summary
النقاط الرئيسية
Revenue declined -2.07% annually over 5 years
ROE of 13.66% — decent returns on equity
Negative free cash flow of -65.78 M
P/E of 11.27 — trading at a low valuation
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 11.76%
النمو
Revenue Growth (5Y)
-2.07%
أقل من متوسط القطاع (1.92%)
Revenue (1Y)9.69%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
الجودة
Return on Equity
13.66%
أعلى من متوسط القطاع (-54.47%)
ROIC-48.30%
Net Margin10.77%
Op. Margin-111.00%
الأمان
Debt / Equity
0.86
أعلى من متوسط القطاع (0.30)
Current Ratio2.19
Interest Coverage-6.95
التقييم
PE (TTM|NTM|2027)
11.27 | 4.65 | 4.73
أعلى من متوسط القطاع (-1.49)
P/B Ratio1.37
EV/EBITDAN/A
Dividend YieldN/A
تاريخ السعر
الاتجاهات المالية
مقارنة الأقران
مقابل وسيط قطاع Manufacturing (1385 نظير)
مقارنة الأقران
مقابل وسيط قطاع Manufacturing (1385 نظير)| المقياس | السهم | وسيط القطاع |
|---|---|---|
| P/E | 11.3 | -1.5 |
| P/B | 1.4 | 1.6 |
| ROE % | 13.7 | -54.5 |
| Net Margin % | 10.8 | -41.5 |
| Rev Growth 5Y % | -2.1 | 1.9 |
| D/E | 0.9 | 0.3 |
السعر المستهدف للمحللين
2 محللين
Buy
الحالي
KWD 2.35
المستهدف
KWD 10.75
KWD 4.50
KWD 10.75
KWD 17.00
التوقعات
مكرر الربحية المستقبلي
4.65
ربحية السهم المستقبلية
KWD 0.51
الإيرادات المقدّرة
135.31 M
تقديرات الأرباح
| الفترة | تقدير ربحية السهم | تقدير الإيرادات | المحللون |
|---|---|---|---|
| FY2027 |
KWD 0.51
-KWD 0.50 – KWD 1.51
|
135.31 M | 2 |
| FY2026 |
-KWD 0.70
-KWD 0.70 – -KWD 0.70
|
81.74 M | 1 |
| الفترة | تقدير ربحية السهم | تقدير الإيرادات | المحللون |
|---|---|---|---|
| 2026 Q2 |
-KWD 0.19
-KWD 0.19 – -KWD 0.19
|
19.41 M | 1 |
| 2026 Q1 |
-KWD 0.22
-KWD 0.22 – -KWD 0.22
|
16.34 M | 1 |
مفاجآت الأرباح
آخر 4 أرباع
| الربع | EPS المقدر | EPS الفعلي | المفاجأة |
|---|---|---|---|
| Q42025 | KWD 0.11 | -KWD 0.21 | -290.9% |
| Q32025 | -KWD 0.63 | KWD 0.11 | +117.6% |
| Q22025 | -KWD 0.31 | -KWD 0.51 | -65.3% |
| Q12025 | -KWD 0.44 | -KWD 0.48 | -9.1% |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 9.69% | Revenue Growth (3Y) | -13.48% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | -2.07% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 63.26 M | Net Income (TTM) | 6.82 M |
| ROE | 13.66% | ROA | 3.99% |
| Gross Margin | N/A | Operating Margin | -111.00% |
| Net Margin | 10.77% | Free Cash Flow (TTM) | -65.78 M |
| ROIC | -48.30% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 0.86 | Current Ratio | 2.19 |
| Interest Coverage | -6.95 | Asset Turnover | 0.37 |
| Working Capital | 64.44 M | Tangible Book Value | 27.19 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | 11.27 | Forward P/E | 4.65 |
| P/B Ratio | 1.37 | P/S Ratio | 1.21 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | 0.57 | Fwd Earnings Yield | 21.51% |
| FCF Yield | -85.64% | ||
| Market Cap | 76.80 M | Enterprise Value | 38.36 M |
| Per Share | |||
| EPS (Diluted TTM) | -0.07 | Revenue / Share | 1.96 |
| FCF / Share | -2.04 | OCF / Share | -2.04 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | -965.18% |
| SBC-Adj. FCF | -98.63 M | Growth Momentum | 11.76 |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 63.26 M | 57.68 M | 84.51 M | 75.74 M | 68.79 M |
| Net Income | 6.82 M | -46.00 M | -60.64 M | -86.58 M | -64.70 M |
| EPS (Diluted) | -0.07 | -2.69 | -8.47 | -0.97 | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -70.22 M | -110.38 M | -142.34 M | -203.56 M | -188.54 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | — | — | 106.07 M | 134.88 M | 128.87 M |
| SG&A Expenses | 96.40 M | 87.73 M | 94.12 M | 113.66 M | 86.84 M |
| D&A | — | — | — | — | — |
| Interest Expense | 10.11 M | 13.53 M | 15.32 M | 12.48 M | 15.31 M |
| Income Tax | -620,000.0 | 312,000.0 | 521,000.0 | 449,000.0 | 473,000.0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 185.55 M | 144.22 M | 167.53 M | 294.30 M | 396.50 M |
| Total Liabilities | 123.37 M | 145.87 M | 165.94 M | 244.28 M | 170.63 M |
| Shareholders' Equity | 49.87 M | 22.74 M | 22.54 M | 41.72 M | 108.67 M |
| Total Debt | 52.42 M | 57.96 M | 60.86 M | 91.73 M | 42.94 M |
| Cash & Equivalents | 79.38 M | 57.26 M | 80.93 M | 178.27 M | 305.74 M |
| Current Assets | 123.84 M | 90.37 M | 117.02 M | 230.43 M | 346.46 M |
| Current Liabilities | 49.74 M | 71.40 M | 84.91 M | 127.72 M | 101.04 M |
{"event":"ticker_viewed","properties":{"ticker":"FBIO","listing_kind":"stock","pathname":"/stocks/fbio","exchange":"NASDAQ","country":"US"}}